Tetraethylene Glycol

Tetraethylene Glycol

SCHEMBL19990177

N=[N+]=N.OCCOCCOCCOCCO

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.73
KMT2A Q03164 3/20 0.73
TSHR P16473 2/20 0.67
MAPK1 P28482 1/20 0.67
THRB P10828 1/20 0.46
HTT P42858 1/20 0.46
MAPT P10636 1/20 0.46
ALDH1A1 P00352 1/20 0.45
APP P05067 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triethylene Glycol SCHEMBL20972932 1.00 MEN1 (0.73) MEN1KMT2ATSHRMAPK1THRB
Di(Hydroxyethyl)Ether SCHEMBL28797624 0.97 TSHR (0.71) MEN1KMT2ATSHRMAPK1THRB
Tetraethylene Glycol SCHEMBL18065765 0.88 MEN1 (0.65) MEN1KMT2ATSHRMAPK1THRB
Triethylene Glycol SCHEMBL18221838 0.88 MEN1 (0.65) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL27833032 0.87 MEN1 (0.55) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL29250406 0.87 MEN1 (0.55) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL27812915 0.87 MEN1 (0.55) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL29251262 0.87 MEN1 (0.55) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL29250825 0.87 MEN1 (0.55) MEN1KMT2ATSHRMAPK1THRB
SCHEMBL5135405 0.86 MEN1 (1.00) MEN1KMT2ATSHRMAPK1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195672-A1 DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTICS TO NEURONS THE JOHNS HOPKINS UNIVERSITY 2025-06-19 US claimed
EP-4504268-A1 DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTICS TO NEURONS The Johns Hopkins University (US) 2025-02-12 EP claimed
CN-119053344-A Dendrimer compositions for targeted delivery of therapeutic agents to neurons 约翰霍普金斯大学 2024-11-29 CN claimed
WO-2023196386-A1 DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTICS TO NEURONS THE JOHNS HOPKINS UNIVERSITY (US) 2023-10-12 WO claimed
US-20260102502-A1 CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY UNIV JOHNS HOPKINS (US) 2026-04-16 US disclosed
US-20250367294-A1 BRANCHED MULTI-FUNCTIONAL MACROMONOMERS AND RELATED POLYMERS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-12-04 US disclosed
EP-4577246-A1 DENDRIMER CONJUGATES OF ANTIDEPRESSANT AND ANTIPSYCHOTIC AGENTS AND THEIR METHODS OF USE The Johns Hopkins University (US) 2025-07-02 EP disclosed
EP-4577245-A1 DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF PSYCHEDELIC THERAPEUTICS The Johns Hopkins University (US) 2025-07-02 EP disclosed
EP-4577247-A1 CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY The Johns Hopkins University (US) 2025-07-02 EP disclosed
WO-2025137151-A2 DENDRIMER COMPOSITIONS FOR THE TREATMENT OF ATHEROSCLEROSIS, OBESITY, AND METABOLIC SYNDROMES THE JOHNS HOPKINS UNIVERSITY (US) 2025-06-26 WO disclosed
US-20250195672-A1 DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTICS TO NEURONS THE JOHNS HOPKINS UNIVERSITY 2025-06-19 US disclosed
CN-119923278-A Dendrimer compositions for targeted delivery of fantasy therapeutic agents 约翰霍普金斯大学 2025-05-02 CN disclosed
US-11338038-B2 Branched multi-functional macromonomers and related polymers and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2022-05-24 US disclosed
CN-111263758-A Branched multifunctional macromers and related polymers and uses thereof 麻省理工学院 2020-06-09 CN disclosed
US-20200164086-A1 FUSOGENIC LIPOSOMES, COMPOSITIONS, KITS AND USE THEREOF FOR TREATING CANCER Apa-advanced Technologies Ltd. (IL) 2020-05-28 US disclosed
EP-3612161-A1 FUSOGENIC LIPOSOMES, COMPOSITIONS, KITS AND USE THEREOF FOR TREATING CANCER APA- Advanced Technologies Ltd. (IL) 2020-02-26 EP disclosed
US-10562863-B2 Heterobifunctional linker THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2020-02-18 US disclosed
CN-110709065-A Fusogenic liposomes, compositions, kits and uses thereof for treating cancer APA先进技术有限公司 2020-01-17 CN disclosed
WO-2018193451-A1 FUSOGENIC LIPOSOMES, COMPOSITIONS, KITS AND USE THEREOF FOR TREATING CANCER APA- ADVANCED TECHNOLOGIES LTD. (IL) 2018-10-25 WO disclosed
US-20180086724-A1 HETEROBIFUNCTIONAL LINKER THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180086724-A1 HETEROBIFUNCTIONAL LINKER MPI, CYBB, CD2BP2 MEN1 2533/4885KMT2A 2070/4885TSHR 4081/4885
US-20200164086-A1 FUSOGENIC LIPOSOMES, COMPOSITIONS, KITS AND USE THEREOF FOR TREATING CANCER FUS, LIPA, HNRNPLL MEN1 2564/4885KMT2A 3233/4885TSHR 3206/4885
US-20250367294-A1 BRANCHED MULTI-FUNCTIONAL MACROMONOMERS AND RELATED POLYMERS AND USES THEREOF MSN, CAD, NEDD8 MEN1 7/4885KMT2A 1679/4885TSHR 4783/4885
US-20250195672-A1 DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTICS TO NEURONS GPR119, SLC2A2, SLC2A1 MEN1 513/4885KMT2A 2116/4885TSHR 1397/4885
US-20260102502-A1 CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY CNR1, CNR2, GPR18 MEN1 4032/4885KMT2A 264/4885TSHR 1425/4885
US-11338038-B2 Branched multi-functional macromonomers and related polymers and uses thereof MSN, CAD, NEDD8 MEN1 7/4885KMT2A 1679/4885TSHR 4783/4885
US-10562863-B2 Heterobifunctional linker MPI, CYBB, CD2BP2 MEN1 2533/4885KMT2A 2070/4885TSHR 4081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.